EPISODE · Aug 15, 2025 · 29 MIN
Emerging DLL3-Targeted Therapies for Extrapulmonary Neuroendocrine Carcinomas
from Decera Clinical Education Oncology Podcast · host Daniel Morgensztern MD, Jonathan Strosberg MD
In this episode, Dr. Daniel Morgensztern and Dr. Jonathan Strosberg discuss the emerging role of DLL3-targeted agents in the management of extrapulmonary neuroendocrine carcinomas, including:The clinical implications of using DLL3 as a therapeutic targetThe impact of emerging DLL3-targeted therapies on evolving treatment paradigmsHow to incorporate DLL3-based treatments into clinical practicePresenters:Daniel Morgensztern, MDProfessor of MedicineClinical Director of Thoracic OncologyWashington University School of MedicineSt Louis, MissouriJonathan Strosberg, MDProfessorDepartment of GI OncologyMoffitt Cancer Center and Research InstituteTampa, FloridaContent based on an online CME program supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Link to full program: https://bit.ly/4mjNPfy Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
What this episode covers
Listen to Dr. Daniel Morgensztern and Dr. Jonathan Strosberg discuss the diagnosis, prognosis, and current limited treatment options for poorly differentiated extrapulmonary neuroendocrine carcinomas, followed by a discussion focusing on emerging DLL3-targeted therapies, including bispecific therapies, antibody–drug conjugates, and CAR T-cell therapies, and their potential roles in improving patient outcomes.
NOW PLAYING
Emerging DLL3-Targeted Therapies for Extrapulmonary Neuroendocrine Carcinomas
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Jan 2, 2026 ·47m
Dec 21, 2025 ·46m